Multidrug-resistant tuberculosis treatment with linezolid-containing regimen

Maham Farshidpour; Golnaz Ebrahimi; Mehdi Mirsaeidi

doi:10.1016/j.ijmyco.2013.09.002

Multidrug-resistant tuberculosis treatment with linezolid-containing regimen

Maham Farshidpour, Golnaz Ebrahimi, Mehdi Mirsaeidi

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

The following is a case of multidrug-resistant pulmonary tuberculosis (MDR-TB) that was treated successfully with a linezolid-containing regimen. It was found that linezolid is an efficient medicine for MDR-TB treatment with an acceptable side effect profile. Treatment was maintained for 18. months, and closely monitoring toxicities did not reveal evidence of any neurologic adverse effects. However, despite our expectation, thrombocytopenia was seen after 2. years follow-up.

Original language	English (US)
Pages (from-to)	233-236
Number of pages	4
Journal	International Journal of Mycobacteriology
Volume	2
Issue number	4
DOIs	https://doi.org/10.1016/j.ijmyco.2013.09.002
State	Published - Dec 2013
Externally published	Yes

Keywords

Linezolid
Multidrug-resistant tuberculosis
Thrombocytopenia
Treatment

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1016/j.ijmyco.2013.09.002

Cite this

@article{98623e3126ed4b03a7405eae70cff318,

title = "Multidrug-resistant tuberculosis treatment with linezolid-containing regimen",

abstract = "The following is a case of multidrug-resistant pulmonary tuberculosis (MDR-TB) that was treated successfully with a linezolid-containing regimen. It was found that linezolid is an efficient medicine for MDR-TB treatment with an acceptable side effect profile. Treatment was maintained for 18. months, and closely monitoring toxicities did not reveal evidence of any neurologic adverse effects. However, despite our expectation, thrombocytopenia was seen after 2. years follow-up.",

keywords = "Linezolid, Multidrug-resistant tuberculosis, Thrombocytopenia, Treatment",

author = "Maham Farshidpour and Golnaz Ebrahimi and Mehdi Mirsaeidi",

year = "2013",

month = dec,

doi = "10.1016/j.ijmyco.2013.09.002",

language = "English (US)",

volume = "2",

pages = "233--236",

journal = "International Journal of Mycobacteriology",

issn = "2212-5531",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Multidrug-resistant tuberculosis treatment with linezolid-containing regimen

AU - Farshidpour, Maham

AU - Ebrahimi, Golnaz

AU - Mirsaeidi, Mehdi

PY - 2013/12

Y1 - 2013/12

N2 - The following is a case of multidrug-resistant pulmonary tuberculosis (MDR-TB) that was treated successfully with a linezolid-containing regimen. It was found that linezolid is an efficient medicine for MDR-TB treatment with an acceptable side effect profile. Treatment was maintained for 18. months, and closely monitoring toxicities did not reveal evidence of any neurologic adverse effects. However, despite our expectation, thrombocytopenia was seen after 2. years follow-up.

AB - The following is a case of multidrug-resistant pulmonary tuberculosis (MDR-TB) that was treated successfully with a linezolid-containing regimen. It was found that linezolid is an efficient medicine for MDR-TB treatment with an acceptable side effect profile. Treatment was maintained for 18. months, and closely monitoring toxicities did not reveal evidence of any neurologic adverse effects. However, despite our expectation, thrombocytopenia was seen after 2. years follow-up.

KW - Linezolid

KW - Multidrug-resistant tuberculosis

KW - Thrombocytopenia

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84888401903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888401903&partnerID=8YFLogxK

U2 - 10.1016/j.ijmyco.2013.09.002

DO - 10.1016/j.ijmyco.2013.09.002

M3 - Article

AN - SCOPUS:84888401903

VL - 2

SP - 233

EP - 236

JO - International Journal of Mycobacteriology

JF - International Journal of Mycobacteriology

SN - 2212-5531

IS - 4

ER -

Multidrug-resistant tuberculosis treatment with linezolid-containing regimen

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this